Next Article in Journal
Inhibition of NADPH Oxidase Activation by Apocynin Rescues Seizure-Induced Reduction of Adult Hippocampal Neurogenesis
Next Article in Special Issue
Integrative Analysis of lncRNAs, miRNAs, and mRNA-Associated ceRNA Network in an Atopic Dermatitis Recurrence Model
Previous Article in Journal
Specific Targeting of Plant and Apicomplexa Parasite Tubulin through Differential Screening Using In Silico and Assay-Based Approaches
Open AccessReview

New Cytokines in the Pathogenesis of Atopic Dermatitis—New Therapeutic Targets

Military Specialist Clinic, Allergy Clinic, ul. Dąbrowskiego 1, 87-100 Toruń, Poland
Department of Dermatology, Venereology and Allergology Medical University of Gdansk, ul. Kliniczna 1a, 80-401 Gdańsk, Poland
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(10), 3086;
Received: 10 September 2018 / Revised: 21 September 2018 / Accepted: 2 October 2018 / Published: 9 October 2018
(This article belongs to the Special Issue Inflammatory Skin Conditions 2018)
Atopic dermatitis (AD) is a recurrent, chronic, and inflammatory skin disease, which processes with severe itchiness. It often coexists with different atopic diseases. The number of people suffering from AD is relatively high. Epidemiological research demonstrates that 15–30% of children and 2–10% adults suffer from AD. The disease has significant negative social and economic impacts, substantially decreasing the quality of life of the patients and their families. Thanks to enormous progress in science and technology, it becomes possible to recognise complex genetic, immunological, and environmental factors and epidermal barrier defects that play a role in the pathogenesis of AD. We hope that the new insight on cytokines in AD will lead to new, individualised therapy and will open different therapeutic possibilities. In this article, we will focus on the cytokines, interleukin (IL)-17, IL-19, IL-33, and TSLP (thymic stromal lymphopoietin), which play a significant role in AD pathogenesis and may become the targets for future biologic therapies in AD. It is believed that the new era of biological drugs in AD will give a chance for patients to receive more successful treatment. View Full-Text
Keywords: atopic dermatitis; cytokines; IL-17; IL-19; IL-33; TSLP; biological agents atopic dermatitis; cytokines; IL-17; IL-19; IL-33; TSLP; biological agents
Show Figures

Graphical abstract

MDPI and ACS Style

Klonowska, J.; Gleń, J.; Nowicki, R.J.; Trzeciak, M. New Cytokines in the Pathogenesis of Atopic Dermatitis—New Therapeutic Targets. Int. J. Mol. Sci. 2018, 19, 3086.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop